---
figid: PMC7456869__fphar-11-01278-g004
figtitle: SARS-CoV-2 in the RAAS pathway
organisms:
- Severe acute respiratory syndrome coronavirus 2
- Influenza A virus
- Coronaviridae
- Severe acute respiratory syndrome-related coronavirus
- Middle East respiratory syndrome-related coronavirus
- H5N1 subtype
- Betacoronavirus
- Murine hepatitis virus
- Human coronavirus 229E
- H3N2 subtype
- Human coronavirus NL63
- Human coronavirus OC43
- Human coronavirus HKU1
- Macropodid alphaherpesvirus 1
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Sar
- Prevotella sp.
organisms_ner:
- Rattus norvegicus
- Homo sapiens
- Mus musculus
- Danio rerio
pmcid: PMC7456869
filename: fphar-11-01278-g004.jpg
figlink: pmc/articles/PMC7456869/figure/f4/
number: F4
caption: SARS-CoV-2 in the RAAS pathway. Prostaglandins stimulate the release of pro-renin
  from juxtaglomerular cells. Pro-renin is cleaved to renin by kallikrein. Renin is
  also produced by activated mast cells. Renin transforms angiotensinogen into angiotensin
  I. ACE or mast cell chymase converts angiotensin I into angiotensin II, which binds
  AT1R, and stimulates the production of aldosterone and subsequently IL-6. Aldosterone
  promotes renal distal tubular reabsorption of sodium, increasing blood pressure.
  In response to intravascular volume expansion, cells in the atrial wall release
  atrial natriuretic peptide (ANP), which down-regulates angiotensin II activity.
  Mononuclear leukocyte-derived aspartate decarboxylase (MLDAD) converts the octapeptide
  angiotensin II to another octapeptide, angiotensin A, which promotes the activation
  or AT1R, or may generate the anti-inflammatory heptapeptide (seven amino acid) ligand,
  alamandine, via ACE2 activity. ACE2 also converts angiotensin II to angiotensin-(1-7),
  which is a ligand for both the Mas receptor and AT2R involved in vasodilation and
  anti-inflammatory responses. Additional aminopeptidases convert angiotensin II into
  angiotensin III and IV. Angiotensin III can bind Mas and both angiotensin III and
  substance P activate MGRPRX2 on mast cells. A lack of ACE2 in RAAS due to SARS-CoV-2-induced
  degradation may suggest a benefit for intervention along the ACE/angiotensin II/AT1R/aldosterone
  pathway. These may include renin inhibitors (Renin-i), AT1R blockers (ARB), ACE
  inhibitors (ACEi), aldosterone blockers (ALDi), or diuretics.
papertitle: COVID-19 Usurps Host Regulatory Networks.
reftext: Colleen S. Curran, et al. Front Pharmacol. 2020;11:1278.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9195615
figid_alias: PMC7456869__F4
figtype: Figure
redirect_from: /figures/PMC7456869__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7456869__fphar-11-01278-g004.html
  '@type': Dataset
  description: SARS-CoV-2 in the RAAS pathway. Prostaglandins stimulate the release
    of pro-renin from juxtaglomerular cells. Pro-renin is cleaved to renin by kallikrein.
    Renin is also produced by activated mast cells. Renin transforms angiotensinogen
    into angiotensin I. ACE or mast cell chymase converts angiotensin I into angiotensin
    II, which binds AT1R, and stimulates the production of aldosterone and subsequently
    IL-6. Aldosterone promotes renal distal tubular reabsorption of sodium, increasing
    blood pressure. In response to intravascular volume expansion, cells in the atrial
    wall release atrial natriuretic peptide (ANP), which down-regulates angiotensin
    II activity. Mononuclear leukocyte-derived aspartate decarboxylase (MLDAD) converts
    the octapeptide angiotensin II to another octapeptide, angiotensin A, which promotes
    the activation or AT1R, or may generate the anti-inflammatory heptapeptide (seven
    amino acid) ligand, alamandine, via ACE2 activity. ACE2 also converts angiotensin
    II to angiotensin-(1-7), which is a ligand for both the Mas receptor and AT2R
    involved in vasodilation and anti-inflammatory responses. Additional aminopeptidases
    convert angiotensin II into angiotensin III and IV. Angiotensin III can bind Mas
    and both angiotensin III and substance P activate MGRPRX2 on mast cells. A lack
    of ACE2 in RAAS due to SARS-CoV-2-induced degradation may suggest a benefit for
    intervention along the ACE/angiotensin II/AT1R/aldosterone pathway. These may
    include renin inhibitors (Renin-i), AT1R blockers (ARB), ACE inhibitors (ACEi),
    aldosterone blockers (ALDi), or diuretics.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Mrgprx2
  - Atr
  - Mrgprd
  - Il6
  - Ar
  - Ace2
  - Nat1
  - Nppa
  - Ace
  - MRGPRX2
  - BEST1
  - ATR
  - ANTXR1
  - MMAB
  - SERPINA2
  - MRGPRD
  - TMT1B
  - IL6
  - AR
  - ACE2
  - ABCD1
  - BRD2
  - MAS1
  - NPPA
  - ACE
  - CMA1
  - SPACA9
  - SPG21
  - EIF4A3
  - FALEC
  - KLK4
  - Mmab
  - Abcd1
  - Soat1
  - Brd2
  - Scn11a
  - Spg21
  - Spaca9
  - Klk1b9
  - Klk1b5
  - Klk1b8
  - atr
  - il6
  - ar
  - ace2
  - nppa
  - ace
  - fgf8a
  - spironolactone
  - furosemide
  - hydrochlorothiazide
  - olemesartan
  - Aldosterone
  - Alamandine
  - ramipril
  - Na
  - aliskiren
  - Prostaglandins
  - ALD
  - Hypertension
  - SARS-COV-2
---
